Analysts expect Exelixis (NASDAQ:EXEL) to post $0.14 earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Exelixis’ earnings, with the highest EPS estimate coming in at $0.20 and the lowest estimate coming in at $0.08. Exelixis posted earnings of $0.08 per share during the same quarter last year, which suggests a positive year over year growth rate of 75%. The business is scheduled to issue its next quarterly earnings results on Wednesday, August 1st.
On average, analysts expect that Exelixis will report full year earnings of $0.86 per share for the current year, with EPS estimates ranging from $0.69 to $1.21. For the next fiscal year, analysts expect that the business will post earnings of $1.10 per share, with EPS estimates ranging from $0.80 to $2.00. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Exelixis.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.12. Exelixis had a return on equity of 77.39% and a net margin of 43.39%. The company had revenue of $120.10 million during the quarter, compared to analysts’ expectations of $120.25 million. During the same period in the previous year, the firm posted $0.12 earnings per share. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year.
EXEL has been the subject of a number of analyst reports. Cann raised Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a report on Tuesday, February 27th. They noted that the move was a valuation call. Stifel Nicolaus boosted their price target on Exelixis from $29.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Monday, February 12th. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. Finally, Zacks Investment Research raised Exelixis from a “sell” rating to a “hold” rating in a report on Monday, March 19th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. Exelixis presently has a consensus rating of “Hold” and a consensus price target of $32.80.
Shares of NASDAQ EXEL traded up $0.02 during trading on Friday, reaching $21.58. The company had a trading volume of 3,719,169 shares, compared to its average volume of 3,388,189. Exelixis has a twelve month low of $18.03 and a twelve month high of $32.50. The stock has a market cap of $6.06 billion, a price-to-earnings ratio of 42.31, a price-to-earnings-growth ratio of 0.52 and a beta of 2.10.
In other news, Director Vincent T. Marchesi sold 15,000 shares of Exelixis stock in a transaction on Friday, May 11th. The stock was sold at an average price of $19.03, for a total value of $285,450.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Patrick J. Haley sold 3,663 shares of Exelixis stock in a transaction on Friday, May 18th. The shares were sold at an average price of $21.61, for a total value of $79,157.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 341,290 shares of company stock valued at $7,754,227. Company insiders own 4.80% of the company’s stock.
Several large investors have recently made changes to their positions in EXEL. TLP Group LLC purchased a new stake in shares of Exelixis in the first quarter valued at $179,000. Sigma Planning Corp purchased a new stake in shares of Exelixis in the fourth quarter valued at $208,000. American International Group Inc. purchased a new stake in shares of Exelixis in the fourth quarter valued at $208,000. Klingenstein Fields & Co. LLC purchased a new stake in shares of Exelixis in the fourth quarter valued at $213,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Exelixis in the first quarter valued at $215,000. 80.21% of the stock is owned by institutional investors and hedge funds.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Get a free copy of the Zacks research report on Exelixis (EXEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.